| Literature DB >> 31873222 |
Yi Yu1, Yijun Guo1,2, Qiqi Tian3, Yuanqing Lan3, Hugh Yeh4, Meng Zhang1, Ipek Tasan3, Surbhi Jain3, Huimin Zhao5,6,7,8.
Abstract
Here, we report a rapid CRISPR-Cas9-mediated gene knock-in strategy that uses Cas9 ribonucleoprotein and 5'-modified double-stranded DNA donors with 50-base-pair homology arms and achieved unprecedented 65/40% knock-in rates for 0.7/2.5 kilobase inserts, respectively, in human embryonic kidney 293T cells. The identified 5'-end modification led to up to a fivefold increase in gene knock-in rates at various genomic loci in human cancer and stem cells.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31873222 PMCID: PMC7085973 DOI: 10.1038/s41589-019-0432-1
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040
Figure 1.Gene KI strategy using Cas9 RNP and end-modified dsDNA donors.
(a) Gene KI rate report system[9]. Double strand break was created at the 3’ UTR of GAPDH gene by Cas9 RNP. Gene KI was mediated by linear dsDNA donor template that contains internal ribosomal entry site (IRES), EGFP sequence and HAs. Red hexagon represents end modification in dsDNA donors. (b) Structures of end modifications tested in this study including 2PS linkages at 5’ ends, 5’ end modifications and 3’ end modifications. These modifications were incorporated as described in online methods. (c) KI rate in HCT116 cells using 2.2 pmol dsDNA donors. PEG10 NHS ester: 1 mM PEG10 NHS ester was added to the transfection reaction; 5’&3’ PEG10: both 5’ C6-PEG10 and 3’ ddU-PEG10 were added. The absolute KI rate for unmodified dsDNA donor is 2.1 ± 0.13%. The size, concentration, and preparation of dsDNA donors were described in Supplementary Table 2. Transfection conditions were described in online methods. Data were collected 7 days post-transfection. p value was calculated by two-tailed unpaired t-test, *p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; n = 3 biologically independent samples. Error bars represent mean ± s.d.
Figure 2.End modified dsDNA donors resulted in enhanced gene KI rate in various applications.
Gene KI rate with (+) or without (−) 5’ C6-PEG10 modifications at (a) GAPDH locus in HCT116, HEK293T, hiPSC WTC G3 and hESC H1; (b) lamin A/C locus in HEK293T; (c) AAVS1 locus and CCR5 locus in hiPSC WTC G3 cells; (d) heterochromatin region 1–4 in HCT116 cells; (e) AAVS1 locus in HEK293T using a 2.5 Kb dsDNA donor; (f) Cpf1-mediated gene KI at GAPDH locus in HEK293T; (g) Duplexed gene KI at GAPDH locus and lamin A/C locus in HEK293T; (h) Allelic-specific gene KI rate at lamin A/C locus in HEK293T. An aliquot of 0.5 M cancer cells or 1.5 M stem cells, 18.8 pmol Cas9, 56.3 pmol gRNA and indicated amount dsDNA donors were used in 100 μL electroporation buffer; for (h), 71.5 pmol Cpf1 and 215 pmol crRNA were used instead. The target sites tested were listed in Supplementary Table 1. The size, concentration, and preparation of dsDNA donors were described in Supplementary Table 2. Transfection conditions were described in online methods. Data were collected 7 days post-transfection (for donors with no promoter) or 10 days post-transfection (for donors contains promoter). p value was calculated by two-tailed unpaired t-test, *p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; n = 3 biologically independent samples. Error bars represent mean ± s.d.